Alaunos Therapeutics, Inc. (TCRT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W

1.8800

+0.0800

(+4.44%)

As of 03:03PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Slow Stochastic

View all chart patterns

Performance Outlook

Previous Close	1.8000
Open	1.8100
Bid	1.8700 x 3100
Ask	1.8800 x 1300
Day's Range	1.7800 - 1.8900
52 Week Range	0.4100 - 2.4300
Volume	893,317
Avg. Volume	3,023,162

Market Cap	405.988M
Beta (5Y Monthly)	0.50
PE Ratio (TTM)	N/A
EPS (TTM)	-0.3150
Earnings Date	Aug 15, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	3.70

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TCRT

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Alaunos Therapeutics, Inc.
Analyst Report: Abbott LaboratoriesAbbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Rating
Fair Value
Economic Moat
4 months agoMorningstar

All

GlobeNewswire
Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results. Register for the live webcast using the link here or by visiting th
- Citi Trends Sets Date for Second Quarter 2022 Earnings Release and Conference Call
  Business Wire
- Zegna Group to Report First Half 2022 Financial Results on Friday, August 26, 2022
  Business Wire
GlobeNewswire
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations
HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations. Dr. Srivastava will lead the Company’s manufacturing operations, including overseeing process optimization and capacity expansion. “Abhi brings extensive experience in cell therapy technical operations, and I am pleased to w
PR Newswire
Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for VRCA, SPRC, ADVM, OCFT, and TCRT.